Skip to main content
. 2018 Jan 23;2:PO.17.00143. doi: 10.1200/PO.17.00143

Fig 3.

Fig 3.

Flow chart of identification of the patients with FGFR3 R248C mutation in the clinical Memorial Sloan Kettering Integrated Molecular Profiling of Actionable Cancer Targets (MSK-IMPACT) cohort. LS, Lynch syndrome; SCC, squamous cell carconima; UC, urothelial carcinoma; UCB, UC of the bladder; UTUC, upper tract UC.